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Infectious human respiratory syncytial virus (RSV) was produced from a cDNA clone that contains 15,222 nucleotides of
RSV genome derived from the A2 strain of subgroup A. Recovery of infectious RSV from cDNA required cotransfection of only
three expression plasmids encoding the nucleoprotein (N), the phosphoprotein (P), and the major polymerase protein (L).
Inclusion of the M2–1 plasmid was not required in the transfection reaction and if included did not significantly increase the
rescue efficiency. However, a single nucleotide substitution in the RSV leader region (C to G at position 4 in the antigenomic
sense), greatly increased the amount of infectious virus recovered from cDNA. A recombinant RSVA2 virus that expresses
an additional structural G protein derived from a subgroup B RSV was also obtained. Both A2 and B strain G glycoproteins
were expressed in cells infected with the chimeric RSV. A chimeric RSV that expresses a heterologous subgroup antigen in
a live attenuated vaccine candidate may be important for prevention of diseases associated with both RSV subgroup A and
subgroup B infection. © 1998 Academic Press
INTRODUCTION
Human respiratory syncytial virus (RSV) is an envel-
oped, single-stranded, negative-sense RNA virus that is
classified in the pneumovirinae subfamily of the
paramyxovirus family (Lamb and Kolakofsky, 1996). The
RSV genome is 15,222 nucleotides (nt) long and contains
10 genes in the following order: 39-NS1-NS2-N-P-M-SH-
G-F-M2-L-59. Each gene transcription unit contains a
short stretch of conserved gene start (GS) sequence and
gene end (GE) sequence. The genomic RNA is tightly
bound by the nucleoprotein (N) and forms a ribonucleo-
capsid (RNP) complex. Also associated with the RNP are
the phosphoprotein (P) and the major polymerase protein
(L). The RSV N, P, and L proteins form the viral RNA-
dependent RNA polymerase for transcription and repli-
cation of the RSV genome (Grosfeld et al., 1995; Yu et al.,
1995). Recent studies indicate that the M2 gene products
(M2–1 and M2–2) are also involved in transcription (Col-
lins et al., 1996; Hardy and Wertz, 1998). The M protein is
a peripheral membrane protein, whereas the F and G
proteins are integral membrane proteins, and they are
involved in virus attachment and viral entry into cells. G
and F proteins are the major antigens that elicit neutral-
izing antibodies in vivo (reviewed in McIntosh and
Chanock, 1990).
RSV is the leading viral cause of pediatric pneumonia
and bronchiolitis (McIntosh and Chanock, 1990). Two
antigenically diverse RSV subgroups A and B are present
in human populations. Antigenic dimorphism is mainly
linked to the G glycoprotein, whereas the F glycoprotein
is more closely related between the subgroups. Cur-
rently, no safe and effective RSV vaccine has been de-
veloped for the prevention of severe morbidity and mor-
tality associated with RSV infection. Formalin-inactivated
virus vaccine failed to provide protection against RSV
infection, and it exacerbated symptoms during subse-
quent infection by the wild-type virus in infants (Chin et
al., 1969; Kapikian et al., 1969). Efforts since have focused
on developing live attenuated temperature-sensitive (ts)
mutants by chemical mutagenesis and/or cold passage
of the wild-type RSV (Gharpure et al., 1969; Crowe et al.,
1994). However, virus candidates were either underat-
tenuated or overattenuated (Kim et al., 1973; Wright et al.,
1976), and some of the vaccine candidates were genet-
ically unstable (Hodes et al., 1974). In addition, several
vaccine candidates were shown to spread to susceptible
contacts and failed to provide protection (Hodes et al.,
1974). New methods are needed to control the degree of
attenuation and to increase the genetic stability of the
attenuated RSV vaccine candidates.
Recovery of infectious virus from cDNA for negative-
strand RNA virus has only been achieved recently (re-
viewed in Conzelmann, 1996; Palese et al., 1996; Roberts
and Rose, 1998). For the nonsegmented RNA viruses,
recovery of infectious viruses from cDNA requires coex-
pression of the N, P and L proteins. For RSV rescue, an
additional expression plasmid encoding M2–1 was re-
ported to be necessary (Collins et al., 1995). The ability to
produce infectious virus from cDNA provides a means to
investigate biological functions of viral proteins and also
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allows the introduction of defined mutations into the
virus genome to attenuate virus for vaccine production
(Juhasz et al., 1997; Whitehead et al., 1998). In this paper,
we report the rescue of infectious RSV from antigenomic
cDNA when cotransfected with the N, P, and L plasmids.
Using this rescue system, we have made a chimeric RSV
that expresses G glycoproteins of both subgroup A and
subgroup B viruses.
RESULTS
Construction of the complete RSV cDNA clone and
recovery of infectious A2 RSV
The schematic diagram of the constructed full-
length cDNA is shown in Fig. 1. The final assembled
full-length RSV antigenomic cDNA was entirely se-
quenced. Comparison with the published RSV A2
strain sequence (Accession No. M74568) indicated a
total of 19 nt differences between our clone and the
published A2 strain. Nine nucleotide differences were
reflective of the differences between the RSV A2
strains. Seven incidental mutations including two si-
lent mutations as genetic markers were introduced
during the cloning procedure, only one resulted in an
amino-acid substitution in the N protein (Thr 24 to Ala).
The functionality of the N, P, and L proteins were
tested for their ability to replicate and transcribe the
minigenome (pRSV/CAT). The mutation in the N protein
did not affect its function as analyzed by the mini-
genome replication assay. A single nucleotide change
(C to G at position 4 of the antigenomic sense) in the
leader region was made (pRSVC4G, Fig. 1A). This
change has been shown to increase transcription/
replication of a RSV minigenome pRSV/CAT by the
expressed N, P, and L proteins (Collins et al., 1993; and
our unpublished observations). We wanted to test if
this single nucleotide substitution in the leader would
also enhance transcription and replication of the RSV
antigenome by the expressed proteins and result in
increased rescue efficiency.
RSV antigenomic cDNA (pRSVC4G) was transfected
into MVA-infected Hep-2 cells together with plasmids
expressing the N, P, and L proteins or together with M2–1
expression plasmid. Numerous infectious foci, showing
typical syncytial formation, were detected from the
dishes infected with the transfected culture supernatant
in the presence or in the absence of the M2–1 expres-
sion plasmid. To determine the effect of the M2–1 plas-
mid on recovery of infectious RSV from cDNA, the
amount of infectious RS viruses recovered from cells
supplied with and without M2–1 expression plasmid was
compared. As shown in Table 1, several independent
experiments showed that the M2–1 expression plasmid
was not required for rescue and if included had little
effect on the quantity of infectious virus recovered.
Infectious RSV (rRSV) was also recovered from pRSV
that contained the wild-type RSV leader sequence. How-
ever, the amount of infectious virus produced from pRSV
was reduced compared to that from pRSVC4G, 1–20
plaques were usually obtained from 0.5 ml of pRSV-
transfected cell culture supernatants compared to 102
plaques obtained when pRSVC4G was used. This con-
firmed that C4G mutation in the leader region indeed
increased the rescue efficiency.
FIG. 1. Schematic diagram of the antigenomic RSV A2 cDNA and construction of chimeric RSV expressing subgroup B glycoprotein G. (A) The
full-length cDNA clone is flanked at its 59 leader (Le) by the T7 RNA polymerase promoter (T7) and at the 39 end trailer (tr) sequence by the hepatitis
delta virus ribozyme (HDV) and the T7 transcriptional terminator (T7T). Three additional G residues were inserted between the T7 promoter and the
leader (Le) sequence. A single nt change in the RSV leader region (C4G in the antigenomic sense) is indicated with an arrow. (B) The RSV B9320 G
gene was inserted into the BglII restriction enzyme site at the F and M2 junction of RSV A2 cDNA. The inserted RSV B9320 G gene is flanked by its
own gene start (GS) and gene end (GE) sequences. The three nt differences in GE sequences of A2 G and F gene with that of B-G are indicated by
the line above the sequences.
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Identification of recombinant RSV
Recovery of recombinant RSV (rRSV and rRSVC4G)
was verified by the presence of two restriction enzyme
site markers that had been introduced into the full-length
RSV cDNA. Recombinant RSV was compared with that of
the laboratory strain A2 virus by RT–PCR using two
primer pairs flanking the introduced restriction markers.
Each cDNA was produced only in the presence of re-
verse transcriptase (RT), indicating that the PCR DNA
was derived from viral RNA (see Fig. 2A, 1 or 2). Diges-
tion of 677-bp DNA from rRSV and rRSVC4G with HpaII
yielded products corresponding to the predicted 154-
and 523-bp fragment (lanes 7 and 8). Digestion of 599-bp
DNA derived from rRSV and rRSVC4G with AciI also
yielded fragments corresponding to the predicted 384-
and 215-bp fragments (lanes 16 and 17). The cDNA de-
rived from the wild-type RSV A2 was not digested by
HpaII (lane 9) or AciI (lane 18), further verifying that the
recovered virus was derived from cDNA.
Protein synthesis by rRSV, rRSVC4G was compared to
that of the wild-type RSV A2 by immunoprecipitation with
goat anti-RSV A2 antibody. As shown in Fig. 2B, viral
protein profiles obtained from rRSVC4G- and rRSV-in-
fected cells were identical to that of the wild-type RSV A2
virus.
Recovery of recombinant RSV A2 expressing G
protein of a subgroup B virus
The RSV B9320 G gene (B-G) was inserted into RSV A2
genome in the intergenic region between the F and M2
gene and contained the GS and GE sequences derived
from RSV B9320 strain (see Fig. 1B). Infectious virus was
produced from MVA-infected Hep-2 cells transfected
with pRSVA2(B-G) along with three plasmids encoding
the RSV N, P, and L proteins. The B-G gene insertion in
the recombinant RSV A2 genome was confirmed by RT–
PCR analysis. As shown in Fig. 3A, a DNA product that is
;1 kb longer than that of A2 virus was obtained from
chimeric rRSVA2(B-G) virus by using a pair of primers
flanking the inserted G gene (lane 1 vs 3). This PCR
cDNA fragment was digested by the unique StuI enzyme
in the B-G gene (lane 5 vs 6). Sequence analysis of this
FIG. 2. Identification of rRSV, rRSVC4G by RT–PCR and analysis of
protein expression. (A) RT–PCR of virion RNA was performed in the
presence (1) or absence (2) of reverse transcriptase (RT) using primer
pairs to amplify DNA spanning the two introduced restriction enzyme
sites. Lanes 1–6: RT–PCR DNA produced from rRSV (lanes 1 and 2),
rRSVC4G (lanes 3 and 4), and wild-type A2 virus (RSV A2, lanes 5 and
6) spanning the HpaII site. DNA obtained from rRSV (lane 7), rRVC4G
(lane 8), and the wild-type A2 virus (lane 9) was digested with HpaII.
Lanes 10–15: RT–PCR DNA from rRSV (lanes 10 and 11), rRSVC4G
(lanes 12 and 13), and the wild-type A2 virus (lanes 14 and 15) spanning
the AciI site. DNA obtained from rRSV (lane 16), rRSVC4G (lane 17), and
the wild-type A2 virus (lane 18) was digested with AciI. M, 100-bp DNA
size marker. (B) Identification of virus specific polypeptides synthesized
by rRSV and wild-type A2 virus in the infected cells. Hep-2 cells were
infected with viruses as indicated and the 35S-radiolabeled cell lysates
were immunoprecipitated with goat anti-RSV serum. The molecular
weight size marker in kilodaltons is indicated on the right of the gel (M).
TABLE 1
Production of Infectious RSV Does Not Require
M2-1 Expression Plasmid
Expt.
Production of infectious RSV
(pfu from 0.5 ml transfection supernatants)
(1) M2-1 (2) M2-1
1 6, 10 (8) 16, 9 (12.5)
2 160, 180 (170) 150, 133 (141.5)
3 588, 253, 725 (522) 300, 1000, 110 (470)
4 120, 46, 428 (198) 100, 122, 105 (109)
Note. Each transfection was performed in duplicate or triplicate. The
average number of plaque forming units (pfu) from 0.5 ml transfected
cell supernatants is shown in parentheses.
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RT–PCR product did not reveal any sequence changes
compared to its cDNA sequence of pRSVA2(B-G). No
nucleotide changes were found in the G gene of the A2
virus.
Expression of G protein of RSV subgroup A and B by
rRSVA2(B-G)
Expression of the inserted RSV B9320 G gene was first
analyzed by Northern blotting using a 32P-labeled oligo-
nucleotide specific to A2-G or B-G mRNA. As shown in
Fig. 3B, both A2-G- and B9320-G-specific RNAs were
detected in rRSVA2(B-G)-infected cells, demonstrating
subgroup specific G mRNA expression. rRSVA2(B-G) chi-
meric virus-infected cells also contained substantial
G-M2 bicistronic transcripts (Fig. 3B, right). The gene end
(GE) sequence of B9320 G gene differs slightly from that
of A2 GE (see Fig. 1B), which may have resulted in the
incomplete transcription termination of the RSV B9320 G
gene.
Protein expression of the chimeric rRSVA2(B-G) was
compared to that of the wild-type RSV B9320 and
rRSVC4G by immunoprecipitation of 35S-labeled infected
Hep-2 cell lysates. The polypeptides were immunopre-
cipitated with polyclonal antiserum raised in goat against
RSV A2 virus (Fig. 4A). A protein that is identical to the
A2-G protein was immunoprecipitated from rRSVA2(B-G)-
infected cells. The G protein of RSV B9320 strain was not
recognized by the anti-A2 antiserum. Subgroup A- and
B-specific G protein expression was analyzed by immu-
noblotting using A2-G-specific mab (Fig. 4B) or B-G-
specific mab (Fig. 4C). Both A2-specific G and B9320-
specific G proteins were detected in rRSVA2(B-G)-
infected cells. Of interest was that the B-G protein
migrated slightly faster than the wild-type B9320 G pro-
tein on the denaturing protein gel. Expression of G gly-
coproteins in rRSVA2(B-G)-infected cells was also con-
firmed by immunostaining of rRSVA2(B-G) plaques using
A2-G-specific mab or B-G-specific mab. As shown in Fig.
5, rRSVA2(B-G) virus plaques were stained by monoclo-
nal antibodies specific to B9320 and A2-G.
Replication of recombinant RSV in tissue culture
Recombinant RS viruses were plaque purified three
times and amplified in Hep-2 cells. Plaque size and
morphology of rRSV was very similar to that of the wild-
type A2 virus (Fig. 6A). However, the plaques formed by
rRSVC4G were smaller than those of rRSV and wild-type
A2 virus. The only known difference between rRSV and
rRSVC4G was a single nucleotide substitution in the RSV
leader region. Therefore, the smaller plaque size of
rRSVC4G was likely due to the change in the leader
function. The plaque size of rRSVA2(B-G) was slightly
smaller than that of rRSVC4G (Figs. 5 and 6). The growth
curves of rRSV, rRSVC4G, and rRSVA2(B-G) were com-
pared to that of the biologically derived wild-type A2
virus. As shown in Fig. 7, the growth kinetics of rRSV is
very similar to that of the wild-type A2 virus. Maximum
virus titers for all the viruses were achieved between 48
FIG. 4. Analysis of A2 and B9320 G proteins expression by rRSVA2(B-
G). (A) Hep-2 cells were infected with viruses as indicated, and the
35S-labeled polypeptides were immunoprecipitated by goat polyclonal
antiserum against RSV A2 strain. Viral-specific proteins are indicated at
the right of the gel. (B) Western blotting of virus infected cells with
antibody specific to A2-G protein. (C) Western blotting of virus infected
cells with antibody specific to B-G protein.
FIG. 3. Identification of chimeric rRSVA2(B-G) by RT–PCR and North-
ern blotting. (A) RT–PCR of rRSVA2(B-G) (lanes 1 and 2) and rRSVA2
(lanes 3 and 4) was performed in the presence (1) or absence (2) of
reverse transcriptase (RT) using a primer pair flanking the B-G insertion
site. A cDNA fragment (lane 1), 1 kb bigger than the cDNA derived from
A2 (lane 3), was produced from rRSVA2(B-G) and was digested by StuI
restriction enzyme unique to the inserted B-G gene (lane 5). A 100-bp
DNA size marker is indicated (M). (B) Northern blot analysis of G mRNA
expression. Total cellular RNA from RSV B9320-, rRSVA2-, and chimeric
rRSVA2(B-G)-infected cells were electrophoresed on a 1.2% agarose gel
containing formaldehyde. The RNA blot was hybridized with a 32P-
labeled oligonucleotide probe specific for A2-G or B9320-G mRNA.
G-M2 bicistronic mRNA in rRSVA2(B-G)-infected cells is also indicated.
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and 72 h. The virus titer of rRSVC4G was ;2.4-fold (at
48 h) and 6.6-fold (at 72 h) lower than rRSV and wild-type
A2 RSV. The chimeric rRSVA2(B-G) virus showed slower
kinetics and lower peak titer.
DISCUSSION
RSV is unique in its gene organization. In addition to
the N, P, L, M, G, and F genes that are common to all the
paramyxoviruses, RSV also contains four additional
genes, which encode five proteins: NS1, NS2, SH, M2–1,
and M2–2. M2–1 and M2–2 are translated from two open
reading frames that overlap in the middle of the M2
mRNA. NS1, NS2, and SH genes had been shown to be
dispensable for RSV growth in tissue culture (Bukreyev et
al., 1997; Karron et al., 1997; Collins et al., personal
communication). M2–1 enhances mRNA transcriptional
processivity and also functions as an antitermination
factor by increasing transcriptional readthrough at the
intergenic junctions (Collins et al., 1996; Hardy and Wertz,
1998), which was reported to be necessary for recover-
ing of infectious RSV from cDNA (Collins et al., 1995).
In this study, we report the construction of a cDNA
containing the RSV genome in antigenomic sense and
rescue of infectious RSV from the cDNA. Upon transfec-
tion of RSV antigenomic cDNA and plasmids encoding
the viral N, P, and L proteins into MVA-infected Hep-2
cells, recombinant RSV bearing the introduced genetic
tags was efficiently recovered. Our finding that the M2–1
expression plasmid is not required for recovery of infec-
tious RSV from cDNA differs from what has been re-
ported earlier (Collins et al., 1995). M2–1 has been
shown to play a role in transcriptional processivity in a
minigenome system, and it is likely that this gene func-
tion is important for virus replication. Recovery of RSV
from cDNA without an additional M2–1 plasmid indicated
that N, P, and L are sufficient to initiate the first round of
replication of the transfected RSV antigenome. It is also
possible that the M2–1 gene could be expressed through
internal initiation from the transfected antigenomic RNA.
Such a case has been reported for the hPIV3 N gene that
is 39 proximal of the virus genome (Hoffman and Baner-
FIG. 5. Immunostaining of virus plaques by monoclonal antibodies
specific to F protein, A2-G, or B-G. Cells were infected with viruses as
indicated, immunostained with respective monoclonal antibodies, and
photographed.
FIG. 6. Plaque morphology of rRSV, rRSVC4G, rRSVA2(B-G), and
wild-type A2 virus (wt A2). Hep-2 cells were infected with each virus
and incubated at 35°C for 6 days. The virus plaques were visualized by
immunostaining and photographed.
FIG. 7. Growth curves of rRSV, rRSVC4G, wild-type A2 RSV (wt A2),
and chimeric rRSVA2(B-G). Hep-2 cells were infected with either virus
at m.o.i. 5 0.5, and the medium was harvested at 24-h intervals. The
titer of each virus was determined in duplicate by plaque assay on
Hep-2 cells.
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jee, 1997). It is difficult to explain the different require-
ments for M2–1 plasmid in the RSV rescue system. The
possibility that T24A substitution in the N protein could
have changed the dependence of the M2–1 plasmid in
the rescue system will be investigated by correcting the
T24 mutation in the antigenomic cDNA. It is not known if
different source of Hep-2 cells could affect the proces-
sivity for viral RNA transcription and eliminate the re-
quirement for the M2–1 plasmid in the RSV rescue sys-
tem. We noted that the overall virus rescue efficiency is
dependent on the condition of the Hep-2 cells. As shown
in Table 1, less virus was recovered from Hep-2 cells that
had gone through .10 in vitro passages (Experiment 1),
which likely resulted in a loss of sensitivity to RSV infec-
tion at or above this passage level (McIntosh and
Chanock, 1990).
rRSV mimics the wild-type A2 virus with regard to
plaque formation efficiency and growth kinetics. How-
ever, rRSVC4G, which contained a single nucleotide sub-
stitution in the RSV leader sequence, formed slightly
smaller plaques and had a relatively lower titer in Hep-2
cells. The single nucleotide change may have affected
the balance between virus RNA transcription and repli-
cation, which we are currently investigating. Neverthe-
less, rRSVC4G was reported to behave similarly to the
wild-type RSV in terms of virulence and replication in
chimpanzees (Whitehead et al., 1998). The rescue effi-
ciency of rRSVC4G is much higher than that of rRSV and
is therefore attractive as a backbone for generation of
mutant viruses.
Two RSV subgroup (A and B) antigens will be needed
in a human vaccine to provide protective immunity. Since
the antigenic differences between subgroup A and B
viruses mostly reside in the G protein, we decided to use
the RSV A2 strain as a vector to express a G protein from
a heterologous subgroup B RSV. This approach would
enable a single virus to function as a ‘‘bivalent vaccine’’
against the two subgroups. The inserted B-G gene, at
RSV A2 F/M2 intergenic region, was flanked by the RSV
B9320 virus gene start and gene end transcription sig-
nals and functioned as a separate transcriptional unit.
Previously, it was shown that RSV replication does not
obey the ‘‘rule of six’’ (Calain and Roux, 1993; Samal and
Collins, 1996), though the total genome length of RSV is
divisible by 6 (15,222). The genome length of pRSVA2(B-G)
was maintained as 6n nucleotides, and 942 nt that en-
code the RSV B9320 G gene were inserted into the RSV
A2 genome. Infectious chimeric RSV, rRSVA2(B-G), was
obtained from cells transfected with pRSVA2(B-G) to-
gether with the N, P, and L expression plasmids. Recov-
ered chimeric rRSVA2(B-G) was viable. The RSV-B9320-
G-specific mRNA and proteins were detected in cells
infected with the chimeric virus. The B-G protein ex-
pressed from rRSVA2(B-G)-infected cells migrated faster
on a denaturing protein gel than the wild-type B9320 G
protein as shown by Western blotting analysis. The in-
troduced B-G gene sequence in the chimeric rRSVA2(B-G)
is identical to the wild-type B9320 G gene as analyzed by
sequencing. It cannot formally be excluded that the mo-
bility difference of the B-G protein is due to different
glycosylation. Much less surface staining was observed
for B-G protein than A2-G protein in rRSVA2(B-G)-infected
cells by immunofluorescence staining (data not shown).
The shortened B-G protein might represent the secreted
form of G protein that was initiated through the second
AUG and result in deletion of 48 amino acids. Truncated
form or secreted G protein has been reported earlier for
RSV (Roberts et al., 1994). The properties of both A2 and
B9320 G proteins in rRSVA2(B-G) virions and in the in-
fected cells are being currently investigated. We will also
abolish the second initiation codon from the B-G gene of
the chimeric rRSVA2(B-G) virus to determine whether the
wild type sized B-G protein could be produced.
The plaque size of chimeric rRSVA2(B-G) is slightly
smaller than that of rRSVC4G, and its virus titer is also
slightly decreased. The reduced growth may be associ-
ated with the increase of genome length. It is also pos-
sible that addition of this foreign gene attenuated the
downstream gene expression (M2 and L genes) and thus
attenuated the chimeric virus. Plaque-size reduction and
delayed growth was also noted for a recombinant RSV
that contained an additional gene encoding CAT
(Bukreyev et al., 1996). The RSV B9320 G gene insert was
stable after serial passages in Hep-2 cells. No evidence
of deletion or substitutions of the inserted B-G was de-
tected by analysis of the RT–PCR DNA derived from
rRSVA2(B-G) vRNA. Because each RSV subtype requires
only one functional G protein, G genes in rRSVA2(B-G)
can undergo either spontaneous mutation or deletion
during virus replication and result in loss of A2-G or B-G
protein function. Therefore, we also carefully examined
the stability of the RSV A2 G gene by sequence analysis
of RT–PCR product and by analyzing the G protein ex-
pressed by the chimeric virus following 10 serial pas-
sages. The data obtained thus far indicate that both the
RSV A2 and B9320 G proteins remain stably expressed
from the chimeric rRSVA2(B-G) infected cells. We are
currently investigating if heteromeric G proteins form in
the infected cells and in virions. Foreign gene expression
by nonsegmented negative-stranded viruses has been
shown for VSV (Kretzschmar et al., 1997), measles virus
(Spielhofer et al., 1998), SV5 (He et al., 1997), and RSV
(Bukreyev et al., 1996). The greatest gene length inserted
into a nonsegmented RNA virus was reported for mea-
sles virus; cDNAs encoding CAT/GFP/b-galactosidase
(total of 5 kb) were inserted into three different intergenic
regions of a recombinant measles virus, and the inserted
genes were found to be very stable after extended pas-
sage (Singh et al., 1997). The size limit of foreign genes
that can be expressed from RSV has not been fully
investigated. RSV may be able to accommodate foreign
genes of .1 kb in length.
Production of recombinant RSV from cDNA has made
it possible to genetically introduce defined mutations
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into virus genome to attenuate RS virus. Using this ap-
proach, the genetic bases for some of the cold-pas-
saged, ts RSV mutants have been determined (Juhasz et
al., 1997). The rescue system has advantages over the
classical cold-passage or chemical mutagenesis strat-
egy in that the degree of virus attenuation can be con-
trolled by introduction of different genotypic markers into
virus genome. The genetic stability of the vaccine can-
didates can also be improved by introduction of multiple
nucleotide changes or by deletions of nonessential
genes. Expression of an additional G protein derived
from a different subgroup makes it possible to use a
single virus as a vaccine candidate to provide protection
against diseases caused by both RSV subgroups. The
utility of the chimeric rRSVA2(B-G) as an RSV vaccine
candidate is currently being evaluated. We have also
constructed a RSV chimeric virus that has the A2 G and
F genes replaced by those of B9320 as an alternative
approach to protecting against RSV subgroup B infection
(Jin et al., unpublished result).
MATERIALS AND METHODS
Cells and viruses
Monolayer cultures of Hep-2 cells were maintained in
minimal essential medium (MEM) containing 10% fetal
bovine serum (FBS). Chicken embryonic kidney (CEK)
cells were also grown in MEM containing 10% FBS.
Modified vaccinia virus Ankara (MVA-T7) expressing bac-
teriophage T7 RNA polymerase (Sutter et al., 1995; Wyatt
et al., 1995) was provided by Dr. Bernard Moss (NIH,
Bethesda, MD) and was grown in CEK cells. MVA virus
titer was determined by TCID50 in CEK cells. The RSV
strains, A2 and B9320, were obtained from the American
Type Culture (ATCC, Rockville, MD).
Construction of cDNA encoding RSV A2 antigenome
The antigenomic cDNA spanning the entire RSV A2
strain genome was assembled into a single molecule by
sequential ligation of RSV cDNA fragments. A total of
seven primer pairs were used to generate cDNA clones
by reverse transcription and polymerase chain reaction
(RT–PCR) of RSV A2 genomic RNA. The final assembled
cDNA (antigenomic sense) was flanked on the leader
end by the promoter for the T7 RNA polymerase. Three
additional G residues were inserted between the T7
promoter and the RSV leader sequence; transcription
would result in the presence of these three nonviral Gs
on the 59 end of the antigenome. To generate the correct
39 end, the cDNA trailer end was constructed to be
adjacent to the hepatitis delta virus ribozyme (Perrotta
and Been, 1991). The ribozyme sequence was followed
by a terminator of the T7 RNA polymerase. The cDNA
clone containing the complete RSV antigenome was des-
ignated pRSV. A cDNA clone that contained a single
C-to-G change at position 4 of the leader sequence
(antigenomic sense) was also obtained and designated
pRSVC4G (Fig. 1A). Both full-length cDNA clones were
modified to contain two genetic tags in the RSV se-
quence: T7214 was changed to C to create HpaII and
G7701 was changed to C to create AciI restriction en-
zyme sites. To ensure the stability of the antigenomic
cDNA, transformation was performed in a bacterial cell
line derived from the Sure cells (Stratagene, La Jolla, CA)
that was tested and shown to support RSV plasmid
replication.
Construction of a RSV cDNA clone encoding an
additional G glycoprotein
A chimeric RSV A2 cDNA containing an insertion of the
G glycoprotein from subgroup B was generated as fol-
lows. A BglII site was introduced at position of 7552 nt
between the F and M2 intergenic junction of RSV in
pRSV-S/B subclone, which contained a SacI (4478 nt) to
BamHI (8500 nt) fragment of RSV sequences, by site-
directed mutagenesis using Quick-change Mutagenesis
kit (Stratagene). The G gene of RSV subgroup B strain
B9320 was amplified from virion RNA by RT–PCR. BglII
sites were incorporated into the PCR primers, which also
included gene start and gene end signals specific for the
B9320 virus G gene (59 GATATCAAGATCTACAATAACAT-
TGGGGCAAATGC 39 and 59 GCTAAGAGATCTTTTTGAA-
TAACTAAGCATG 39). The RSV B9320 G gene fragment
(B-G) was inserted at the BglII site in pRSV-S/B (Fig. 1B),
and the SacI to BamHI restriction fragment with B-G inser-
tion was then cloned into pRSVC4G. The resulting RSV
antigenomic cDNA clone was designated pRSVA2(B-G).
Transfection and recovery of recombinant RSV
The RSV expression plasmids encoding the N, P, and
L were cloned in pCITE vector under the control of T7
RNA polymerase promoter. To rescue RSV from cDNA,
monolayers of Hep-2 cells (80% confluent) were infected
with MVA-T7 at m.o.i. 5 5 and incubated at 35°C for 60
min. The cells were then transfected with a full-length
RSV cDNA and plasmids encoding the N, P, and L by
LipofecTACE (Gibco BRL, Gainthersburg, MD). In a sep-
arate set of transfection, pCITE-M2–1 was also included
in addition to the N, P, and L. The amounts of the plas-
mids added were as follows: 0.4 mg pRSV, 0.4 mg
pCITE-N and pCITE-P, 0.2 mg pCITE-L, and 0.4 mg pCITE-
M2–1. After incubation of the transfected Hep-2 cells for
5 h or overnight, the transfection medium was replaced
with MEM containing 2% FBS and the cells were incu-
bated at 35°C for 3 days. The rescued viruses were
enriched by amplification in fresh Hep-2 cells. After 6
days infection, the culture supernatant was harvested,
the cells fixed with methanol, and virus-infected cells
detected by immunostaining. A mixture of four murine
monoclonal antibodies specific to the RSV F protein
(Beeler and van Wyke Coelingh, 1989) was used, fol-
lowed by a goat anti-mouse antibody linked to horse-
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radish peroxidase (DAKO, Carpinteria, CA). The virus-
infected cells were then identified by addition of the
AEC-chromogen substrate (DAKO) according to the man-
ufacturer’s instructions. Rescued viruses from the posi-
tive wells were plaque purified and amplified in Hep-2
cells. The virus titer was determined by plaque assay on
Hep-2 cells.
Characterization of recombinant RSV
For RT–PCR analysis, viral RNA was extracted from
250 ml of infected cell culture supernatant by an RNA
extraction kit (RNA Stat-50, Tel-Test, Friendswood, TX)
and was reverse transcribed using an appropriate primer
that annealed to vRNA. An aliquot of the cDNA was then
amplified using the appropriate primer pairs. PCR was
carried out at 94°C for 30 s, 50°C for 30 s, and 72°C for
2 min for 25 cycles. The DNA product was purified by
QIAquick PCR purification kit (Qiagen, Santa Clarita, CA)
and digested with appropriate restriction enzymes.
Viral specific proteins produced from the infected cells
were analyzed by immunoprecipitation of the infected
cell extracts or by Western blotting. For immunoprecipi-
tation analysis, virus infected cells were labeled with
35[S]promix (100 mCi/ml 35[S]Cys and 35[S]Met, Amer-
sham, Arlington Heights, IL) at 14–18 h p.i. The cell
monolayers were lysed by RIPA buffer and polypeptides
immunoprecipitated by polyclonal anti-RSV A2 serum
(Biogenesis, Sandown, NH). Immunoprecipitated poly-
peptides were electrophoresed on 10% polyacrylamide
gels containing 0.1% SDS and detected by autoradiogra-
phy. For Western blotting analysis, virus-infected cell
lysates were electrophoresed on SDS–PAGE and poly-
peptides transferred to nitrocellulose membrane. Immu-
noblotting was performed as described in Jin et al.
(1997), using a monoclonal antibody specific to G protein
of RSV A2 strain (2313CD7) or a mixture of four mono-
clonal antibodies specific to G protein of RSV B strain
(2434DB3, 2218BD5, 2218AE7, and 2218DG7) obtained
from Dr. G.A. Storch (Storch et al., 1988).
For Northern blot analysis, total cellular RNA was
extracted from infected Hep-2 cells at 48 h p.i. by a RNA
extraction kit (RNA stat-60, Tel-Test). RNA was electro-
phoresed on a 1.2% agarose gel containing formalde-
hyde and transferred to a nylon membrane (Amersham).
An oligonucleotide specific to the G gene of the A2 strain
(59 TCTTGACTGTTGTGGATTGCAGGGTTGACTTGACTC-
CGATCGATCC 39) or an oligonucleotide specific to the
B9320 G gene (59 CTTGTGTTGTTGTATGGTGTGTTTCTG-
ATTTTGTATTGATCGATCC 39) was labeled with [32P]ATP
by a kinasing reaction. Hybridization of membrane with a
32P-labeled oligonucleotide probe was performed at
65°C and washed according to standard procedures.
Growth analysis of recombinant RSV in tissue culture
Hep-2 cells were grown in T25 culture flasks and
infected with rRSV or wild-type RSV A2 strain at m.o.i. 5
0.5. After 1 h absorption at 37°C, the cells were washed
three times with MEM containing 2% FBS and incubated
at 37°C in 5% CO2. At various times p.i., 250 ml of the
culture supernatant was collected, and stored at 270°C
until virus titration. Each aliquot taken was replaced with
an equal amount of fresh medium. Plaque assays were
performed in Hep-2 cells on 12-well plates using an
overlay of 1% methylcellulose and 1 3 L15 medium
containing 2% FBS. After incubation at 35°C for 6 days,
the monolayers were fixed with methanol and plaques
identified by immunostaining.
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